Elanco Statement of Safety of Seresto®

Elanco takes the safety of our products very seriously, and thoroughly investigates potential concerns related to their use. It is critically important to understand that a report is not an indication of cause. Since its initial approval in 2012, more than 25 million Seresto collars have protected dogs and cats in the U.S. from fleas, ticks and the resulting tick-borne illnesses that can impact their quality of life.

There is no established link between death and exposure to the active ingredients contained in Seresto. The reporting rate for all adverse events related to Seresto is less than 0.3% of all collars sold since 2012 - defined by the WHO (World Health Organization) as “uncommon”. The significant majority of these incidents relate to non-serious effects such as application site disorders – reddening of the skin or hair loss below the collar. As a globally marketed product, more than 80 regulatory authorities around the world, including the US EPA, rigorously reviewed the safety data collected over the course of Seresto’s development prior to registration and/or approval, as appropriate. Further, the safety and efficacy of Seresto are continuously monitored and scrutinized by global regulatory bodies as well as via internal processes.